



## Cancer Prevention and Control CIRB Meeting Agenda

January 27, 2022

---

---

### I. Continuing Review ReReview

**S1614**, A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors (Protocol Version Date 06/03/21)

---

---

### II. Continuing Review

**A191901**, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Protocol Version Date 11/09/20)

---

---

### III. Continuing Review

**NRG-CC003**, Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer (Protocol Version Date 04/13/21)

---

---

### IV. Continuing Review

**URCC-16092**, Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients with Cancer (Protocol Version Date 04/22/20)

---

---

### V. Continuing Review

**UWI2015-05-01**, Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect (Protocol Version Date 04/14/21)

---

---

### VI. Continuing Review

**WF-1805CD**, Implementation and Effectiveness Trial of HN-STAR (Protocol Version Date 10/04/21)

---

---

**VII. New Study - Initial Review**

**A212102**, Blinded Reference Set for Multicancer Early Detection Blood Tests (Protocol Version Date 12/09/21)

---

---

**VIII. New Study - Initial Review**

**INT21-05-01**, Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome (Protocol Version Date 11/30/21)

---

---

**IX. Amendment ReReview**

**A231701CD**, Increasing Socioeconomically Disadvantaged Patients' Engagement in Breast Cancer Surgery Decision-Making Through a Shared Decision Making Intervention (Protocol Version Date 01/05/22)

---

---

**X. Amendment**

**UWI2015-05-01**, Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect (Protocol Version Date 12/17/21)

---

---